Nextera appoints new CEO

Nextera appoints new CEO

Oslo, Norway, 02.11.2012
Nextera is delighted to announce the appointment of Thomas Andersen as new CEO. He has significant business development experience from the pharmaceutical and biotech industry. Thomas Andersen has been working for Pronova BioPharma the last 5 years, with responsibility for the US market. Prior to Pronova, Andersen spent 8 years at AstraZeneca in various roles.

Hans Ivar Robinson, Chairman of Nextera, welcomes the appointment. "Nextera will move into a new stage during the next couple of years. The appointment of Thomas Andersen will, together with the current dedicated team, enable the company to execute key strategies and plans, and bring Nextera to the next level. I am convinced that Thomas Andersen with his capabilities, energy and motivation will be an important asset and leader to the company."

"I see Nextera as an excellent opportunity, Thomas Andersen comments. "The technology is highly innovative and has a huge commercial potential. I really look forward to working with the excellent people in the company as well as with the board and external stakeholders. "

Contact: Hans Ivar Robinson, Chairman of the Board, tel. +47 90 87 14 83.

About Nextera
Nextera is a drug discovery company based on a proprietary phage display technology. Its focus will be on new therapies for autoimmune diseases and on cancer. The key innovative elements is Nextera's unique Phagemer technology enabling antigen specific CD4+ T cell detection and epitope discovery of HLA class 2 expressed antigens.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.